Corrigendum

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma

Benjamin Ory, Matthew R. Ramsey, Catherine Wilson, Douangsone D. Vadsirisack, Nicole Forster, James W. Rocco, S. Michael Rothenberg, and Leif W. Ellisen


Citation for this corrigendum: J Clin Invest. 2014;124(3):1418. doi:10.1172/JCI75406.

During the assembly of Figure 1A of this manuscript, incorrect β-tubulin immunoblots were inadvertently included. The authors were unable to retrieve the original raw data; however, results from a replicate experiment are shown in the corrected figure panel below.

The authors regret the error.

Corrigendum

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Violeta Serra,1 Pieter J.A. Eichhorn,2 Celina García-Garcia,1 Yasir H. Ibrahim,1 Ludmila Prudkin,3 Gertrudis Sánchez,5 Olga Rodríguez,1 Pilar Antón,1 Josep-Lluís Parra,4 Sara Marlow,2 Maurizio Scaltriti,6 José Pérez-Garcia,7 Alex Prat,8 Joaquín Arribas,9,10 William C. Hahn,10,11 So Young Kim,12 and José Baselga1,6

1Experimental Therapeutics, Vall d’Hebron Institute of Oncology, Barcelona, Spain. 2Cancer Science Institute of Singapore, National University of Singapore, Singapore. 3Molecular Pathology and 4Growth Factors Groups, Vall d’Hebron Institute of Oncology, Barcelona, Spain. 5Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. 6Human Oncology and Pathogenesis Program and Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 7Breast Cancer and Melanoma Group and 8Translational Genomics Unit, Vall d’Hebron Institute of Oncology, Barcelona, Spain. 9Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. 10Center for Cancer Genome Discovery, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. 11Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. 12Department of Molecular Genetics and Microbiology, Duke RNAi Screening Facility, Duke University Medical Center, Durham, North Carolina, USA.


Citation for this corrigendum: J Clin Invest. 2014;124(3):1418. doi:10.1172/JCI75534.

The affiliation for Joaquín Arribas was incorrect. The correct affiliation list is above.

The authors regret the error.